|
1.4 BIOLOGIE - TECHNOS
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
U.S. judge to allow controversial evidence in Roundup cancer trials [Reuters]
|
|
|
|
|
|
Plaintiffs’ lawyers contended some evidence of corporate misconduct was inextricably linked to their scientific claims. The judge appeared to agree with them, saying it was difficult to draw the line between scientific evidence and allegations of corporate misconduct, and questioned whether it would be fair for the jury to not hear about the company’s alleged attempts to influence scientists.
|
|
|
|
|
|
|
3.4.1 CHIMIOPRÉVENTION - ASPIRINE
|
|
|
Aspirin and the treatment of cancer [The Guardian]
|
|
|
|
|
|
A meta-analysis shows a 24% reduction in cancer deaths and a 19% reduction in deaths from all causes in patients taking aspirin. That is: at any time after a diagnosis of cancer, about 19% more patients taking aspirin are alive, compared with patients not taking aspirin.
|
|
|
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
Persistent sore throat 'can be cancer sign' [BBC News]
|
|
|
|
|
|
"The significance of the study really is that we've found that hoarseness is important for laryngeal cancer, but significantly the risk of having laryngeal cancer greatly increases when it's combined with a recurrent sore throat."
|
|
|
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
How the Body Fights Cancer and Intruders [Caltech]
|
|
|
|
|
|
Determining a given T cell's target is a critical step in designing personalized treatments for cancers and developing vaccines. Now, a team of Caltech scientists has developed two new methods for rapidly determining T cell targets.
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
Health Affairs study misses the mark on medicine costs [PhRMA]
|
|
|
|
|
|
A recent study published in Health Affairs concludes that list price inflation for existing brand medicines is a key driver of rising medicine spending. However, by failing to account for the substantial rebates and discounts that payers negotiate for many brand medicines, this study dramatically overestimates the role of list price increases.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.10 POLITIQUES
|
|
|
The impact of Brexit on the regulatory and marketing landscape [RAPS]
|
|
|
|
|
|
While Brexit is certain to impact the development, manufacture and sale of drugs, the ongoing lack of clarity on the future relationship between the UK and EU makes gauging the precise impact very difficult. The following predictions for 2019 are based on those certainties that are available at the time of going to press.
|
|
|
|
|
|
|
6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|
The robot needs a human heart—why AI in medicine brings moral choices into focus [BMJ]
|
|
|
|
|
|
Although the hype around AI suggests it is a panacea for improving healthcare, equal focus now needs to be placed on the inherent challenges to humanity as well as the challenges in computing. Social scientists need to be let back into the room, sharing a table with computer scientists, healthcare professionals, politicians and, importantly, patients.
|
|
|
|
|
|
|
6.8 COMMUNICATION
|
|
|